Brokerages Set VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Price Target at $0.95

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) has received an average rating of “Reduce” from the five ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $0.95.

Separately, Wall Street Zen lowered VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st.

VistaGen Therapeutics Stock Up 1.6%

Shares of VistaGen Therapeutics stock opened at $0.65 on Friday. The stock’s fifty day moving average is $0.60 and its 200-day moving average is $1.44. VistaGen Therapeutics has a 12-month low of $0.43 and a 12-month high of $5.14. The firm has a market capitalization of $25.63 million, a PE ratio of -0.34 and a beta of 0.31.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Cubist Systematic Strategies LLC acquired a new position in VistaGen Therapeutics in the 1st quarter worth about $25,000. Schonfeld Strategic Advisors LLC acquired a new position in VistaGen Therapeutics in the 3rd quarter worth about $39,000. Millennium Management LLC bought a new stake in shares of VistaGen Therapeutics during the 3rd quarter worth about $73,000. Bank of America Corp DE boosted its stake in shares of VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after acquiring an additional 19,331 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new stake in shares of VistaGen Therapeutics during the 3rd quarter worth about $112,000. 78.39% of the stock is owned by institutional investors and hedge funds.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.